›› 2019, Vol. 39 ›› Issue (12): 1456-.doi: 10.3969/j.issn.1674-8115.2019.12.019

• Review • Previous Articles     Next Articles

Progress in antidepressant effects of pioglitazone

SHI Yi-fan, HUANG Jia, FANG Yi-ru   

  1. 1. Division of Mood Disorder, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; 2. CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai 200030, China; 3. Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, China
  • Online:2019-12-28 Published:2020-02-06
  • Supported by:
    National Key R&D Program of China, 2016YFC1307100; National Natural Science Foundation of China, 81771465

Abstract: As an agonist of peroxisome proliferator-activated receptor γ (PPARγ), pioglitazone may be involved in the regulation of glycolipid metabolism, oxidative stress and immune inflammatory response, thereby improving depression. Studies find that pioglitazone is effective in treating depression, especially in patients with resistance and comorbid metabolic syndrome, and is expected to be a new treatment for depression. This article reviews the research progress of pioglitazone in clinical application and related mechanisms of depression, into provide theoretical basis and support for subsequent research.

Key words: pioglitazone, depressive disorder, peroxisome proliferator-activated receptor γ